CN-116284249-B - Polypeptide BPKR and application thereof in breast cancer treatment

Abstract

The invention discloses a polypeptide BPKR and application thereof in breast cancer treatment, and a polypeptide BPKR, the amino acid sequence of which is Lys-Thr-Asp-Pro-Val-Leu-Arg-Ser-Leu-Glu-Gly-Leu-Val-Gly-Leu-Gln-Asn-Ile-Arg. The polypeptide BPKR has the activity of inhibiting proliferation of breast cancer cells.

Inventors

• YANG LONGFEI
• MU SHIJIE
• TANG QISHENG
• ZHONG YAN

Assignees

• 中国人民解放军空军军医大学

Dates

Publication Date

20260512

Application Date

20230216

Priority Date

20220722

Claims (3)

1. 1. The polypeptide BPKR is characterized in that the amino acid sequence is KTDPVLRSLEGLVGLQNIR.
2. 2. The use of the polypeptide BPKR according to claim 1 in the manufacture of a medicament for the treatment of breast cancer.
3. 3. A breast cancer therapeutic comprising the polypeptide BPKR of claim 1.

Description

Polypeptide BPKR and application thereof in breast cancer treatment Technical Field The invention belongs to the technical field of polypeptide medicaments, and particularly relates to a polypeptide BPKR and application thereof in breast cancer treatment. Background Breast cancer is one of the most common malignant tumors of females, and is a malignant tumor which seriously affects the physical and mental health and life of females. The number of new and dead breast cancers in China is 12.2% and 9.6% of the world each year, respectively. The treatment of breast cancer becomes a great challenge in the field of clinical treatment in China. The treatment method of breast cancer mainly comprises operation treatment, chemotherapy, radiation treatment, endocrine treatment and biological treatment, including molecular targeting treatment, etc. The molecular targeting therapy is mainly specific monoclonal antibody therapy adopted by breast cancer patients with positive specific proteins such as HER-2 and the like, is generally carried out after the completion of postoperative adjuvant chemotherapy, and can also be carried out simultaneously with radiotherapy. However, in breast cancer treatment, available medicines are limited, and when patients have drug resistance, it is difficult to find suitable alternative medicines, so more effective medicines for breast cancer treatment need to be developed. The research of polypeptide antitumor drugs is always highlighted, and the polypeptide antitumor drugs have potential application value in antitumor prodrugs, and provide new lead prodrugs for targeted treatment of tumors. The polypeptide medicament has the characteristics of strong specificity, good targeting, obvious curative effect, high safety and the like, and can well prolong the life cycle of a patient and improve the life quality of the patient in the anti-tumor treatment process, so that the research and development of the polypeptide anti-tumor medicament has good application prospect in the development of new tumor treatment medicaments. Disclosure of Invention The invention aims to provide a polypeptide BPKR and application thereof in breast cancer treatment, which have the activity of inhibiting proliferation of breast cancer cells. The invention adopts the following technical scheme that the polypeptide BPKR has an amino acid sequence of Lys-Thr-Asp-Pro-Val-Leu-Arg-Ser-Leu-Glu-Gly-Leu-Val-Gly-Leu-Gln-Asn-Ile-Arg. Further, the molecular formula is C 92H163N29O27, and the molecular weight is 2107.45g/mol. The invention also discloses a derivative of the polypeptide BPKR, which is obtained by modifying and reforming the skeleton of the polypeptide BPKR. The invention also discloses application of the polypeptide BPKR in preparation of a breast cancer cell proliferation inhibitor. The invention also discloses application of the polypeptide BPKR in preparing MDA-MB-231 and MCF-7 cell proliferation inhibitors. The application of the polypeptide BPKR in preparing breast cancer cell proliferation inhibitor is used for inhibiting the growth of MDA-MB-231 and/or MCF-7 cells. The invention also discloses a breast cancer therapeutic drug, which comprises the polypeptide BPKR or the derivative of the polypeptide BPKR. The polypeptide BPKR has the beneficial effects of inhibiting the proliferation activity of breast cancer cells, and providing a new drug candidate and a material basis for the treatment of breast cancer. Drawings FIG. 1 is an ESI-MS identification of a polypeptide BPKR; FIG. 2 is a diagram of RP-HPLC analysis of polypeptide BPKR; FIG. 3 is a schematic diagram of MTT assay of tumor suppressing activity of polypeptide BPKR; 3a is the time dependent growth curve of MDA-MB-231 cells; 3b is a time dependent growth curve of MCF-7 cells; FIG. 4 is a flow cytometer analysis diagram of apoptosis induced by polypeptide BPKR in a breast cancer cell line; 4a is 4 b; 4b is an apoptosis induction pattern of MDA-MB-231 cells 48h after addition of the polypeptide BPKR of example 1; 4c is a blank of 4 d; 4d is a graph of apoptosis induction 48h after addition of polypeptide BPKR of example 1 to MCF-7 cells. Detailed Description The invention will be described in detail below with reference to the drawings and the detailed description. The amino acid sequence of the polypeptide BPKR is Lys-Thr-Asp-Pro-Val-Leu-Arg-Ser-Leu-Glu-Gly-Leu-Val-Gly-Leu-Gln-Asn-Ile-Arg. The molecular formula is C 92H163N29O27, and the molecular weight is 2107.45g/mol. The invention also discloses a derivative of the polypeptide BPKR, which is obtained by modifying and reforming the skeleton of the polypeptide BPKR. The invention also discloses application of the polypeptide BPKR in preparation of a breast cancer cell proliferation inhibitor. The invention also discloses application of the polypeptide BPKR in preparing MDA-MB-231 and MCF-7 cell proliferation inhibitors. The application of the polypeptide BPKR in preparing breast cancer cell prolifer